This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Sign In   |   Register
2016: EAS-FHSC Symposium on FH - Programme

Programme for download

Friday, November 25, 2016

12.00 onwards Arrival, registration
  14.00 Opening & Welcome
M Banach (PL), M Vrablík (CZ), K Ray (UK), A Catapano (IT)
Session 1: Familial hypercholesterolaemia in 2016: from epidemiology to diagnosis
  14.15 Role of lipids in the atherogenesis: the case of FH
Speaker: G Latkovskis (LAT)
Commentator: P Jankowski (PL)
  15.00 Epidemiology and clinical picture of FH
Speaker: M Gruchala (PL)
Commentator: M Ezhov (RU)
  15.45 Genetics of FH: FH is not a single disease
Speaker: JA Kuivenhoven (NL)
Commentator: B Vohnout (SK)
  16.30 Diagnostic criteria for FH (DLNC, Simone Broom, MedPed)
Speaker: M Vrablík (CZ)
Commentator: D Pella (SK)
 Session 2 Groupwork: case presentations and discussion
  17.30-19.00 Case presentations and group discussions (4 groups with 2 Experts/Chairs in each; the same cases and presentations in each group)
Group 1: M Banach (PL), Z Fras (SI)
Group 2: M Vrablík (CZ), H Soran (UK)
Group 3: K Ray (UK), M Ezhov (RU)
Group 4: A Catapano (IT), G Latkovskis (LAT)
Saturday, November 26, 2016
Session 3 Current FH screening activities
  09.00 Screening for FH: universal, opportunistic or cascade screening?
Speaker: S Romeo (SWE)
Commentator: Z Fras (SI)
  09.45 Collaborative efforts in FH identification: THE FHSC INITIATIVE
Speaker: K Ray (UK)
Panel discussion: M Banach (PL), A Catapano (IT), R Ceska (CZ), L Tokgozoglu (TK), M Vrablik (CZ)
  10.45 Registries: from set up to practical problems
Speaker: G K Hovingh (NL)
Commentator: G Latkovskis (LAT)
  11.30 Imaging of atherosclerosis in FH
Speaker: L Tokgozoglu (TK)
Commentator: K Ray (UK)

  12.30 Lunch
Session 4 Therapeutic consideration for FH patients in 2016 and beyond
  13.30 Real challenge in the optimal therapy: statin non-response, non-adherence, statin discontinuation
Speaker: M Banach (PL)
Commentator: D Gaita (RO)

  14.15 LDL-apheresis vs new drugs (PCSK9 inhibitors) - when, whom, why?
Speaker: H Soran (UK)
Commentator: A Rynkiewicz (PL)
  15.00 FH in special populations: children
Speaker: A Brandt (PL)
Commentator: M Kayikcioglu (TK)

  15.45 Coffee break
Session 5 Workshops: Special chapters of FH management
  16.00-18.30 Workshops (group divided into 3 parts, rotating in 45 minutes; 2 experts in each group)
    - FH management in statin intolerance
M Banach (PL), M Rizzo (IT)
    - CVD risk assessment in FH: are all the FH patients created equal?
K Ray (UK), E Moses (GR)
    - Management of FH in special populations (pregnancy, children, concomitant diseases)
H Soran (UK)
D Lighezan (RO)
Sunday, November 27, 2016
Session 6 08.00-09.30 Central & European Countries Key Opinion Leader Summit
A Catapano (IT), M Kayikcioglu (TK), E Michenko (UKR), E Mirrakhimov (KYR), B Pojskic (BOSNIA), I Gouni-Berthold (GER), M Viigimaa (EE), K Lalic (SER)
Session 7 Severe and Severe and homozygous FH
  09.30 Severe FH: diagnosis and management
Speaker: T Freiberger (CZ)
Commentator: A Susekov (RU)
  10.15 Identification and management of homozygous FH
Speaker: I Gouni-Berthold (GER)
Commentator: B Vohnout (SK)

  11.00

Current guidelines for FH treatment: EAS consensus papers
Speaker: A Catapano (IT)
Commentator: M Viigmaa (LIT)

  12.00-13.00 Conclusion and Take Home Message
A Catapano (IT), K Ray (UK), M Banach (PL), M Vrablík (CZ)
Membership Software Powered by YourMembership  ::  Legal